
    
      This is a non-randomized Phase 1 study to evaluate the preliminary safety and efficacy of
      hematopoietic gene therapy consisting of autologous CD34+ enriched hematopoietic cells
      transduced with the lentiviral vector (LV) carrying the human TCIRG1 transgene (RP-L401) in
      pediatric patients with IMO. Following myeloablative conditioning patients will receive an
      infusion of the genetically modified hematopoietic stem and progenitor cells (HSPCs).
    
  